for the maintenance treatment of copd

dual bronchodilation,

down to a science

Not indicated for the relief of acute bronchospasm or for the treatment of asthma.

Adverse reactions with BEVESPI AEROSPHERE with a ≥2% incidence and more common than placebo were urinary tract infection and cough.1

MAXIMIZE BRONCHODILATION1,2†>>

Improved lung function including predose FEV1 and peak FEV1 at 24 weeks1,2

In a separate study vs placebo, improvement in peak inspiratory capacity at Day 293‡

INTELLIGENT FORMULATION1>>

Intelligent formulation for a pMDI§ using patented, phospholipid-based
AEROSPHERE™ Delivery Technology1

*Initial treatment in Group B patients with severe breathlessness and in Group D patients.

Defined as superior improvements in lung function relative to its individual components and placebo in two 24-week pivotal trials (n=3699).

In a separate Phase IIIb trial (n=35), there was a significant mean improvement in primary endpoint FEV1 AUC0-24 on Day 29 vs placebo. Peak inspiratory capacity after the evening dose on Day 29 was a secondary endpoint. Similar results seen in a second Phase IIIb trial (n=75).

§BEVESPI AEROSPHERE is a pMDI containing the LAMA glycopyrrolate and LABA formoterol fumarate, along with phospholipid porous particles that form the co-suspension with the micronized drug crystals.